SOURCE: Cannabis Therapy Corp.

Cannabis Therapy Corp.

April 23, 2014 09:00 ET

Cannabis Therapy Corp. Confirms Bio-Med Executive Vered Caplan as Board Member

Company Builds and Extends Expert Business Oversight With Latest Appointment

NEW YORK, NY--(Marketwired - Apr 23, 2014) - Cannabis Therapy Corp. (OTCQB: CTCO) (the "Company") a development stage enterprise focused on the business of manufacturing and marketing pharmaceutical level products containing phytocannabinoids, an abundant and pharmaceutically active component of cannabis, for the treatment of various conditions and diseases, is pleased to confirm and welcomes the senior executive level appointment of Ms. Vered Caplan to its Board of Directors.

Ms. Caplan is currently the CEO of Orgenesis, Inc., a development stage company offering therapeutic technology as a treatment for diabetes. Ms. Caplan was previously Chief Executive Officer of Kamedis, a company focused on utilizing plant extracts for dermatology purposes. From 2004 to 2007, Ms. Caplan was Chief Executive Officer of GammaCan, a company focused on the use of immunoglobulins for the treatment of cancer. During the previous five years, Ms. Caplan has been a director of the following companies: Opticul Ltd., a company involved with optic based bacteria classification; Inmotion Ltd., a company involved with self-propelled disposable colonoscopies; Nehora Photonics Ltd., a company involved with non-invasive blood monitoring; Ocure Ltd., a company involved with wound management; Eve Medical Ltd., a company involved with hormone therapy for Menopause and PMS; and Biotech Investment Corp., a company involved with prostate cancer diagnostics. Ms. Caplan has a M.Sc. in bio-medical engineering from Tel-Aviv University specialized in signal processing; management for engineers from Tel-Aviv University specialized in business development; and a B.Sc. in mechanical engineering from the Technion Institute of Technology specialized in software and cad systems.

Cannabis Therapy Corp President & CEO Soren Mogelsvang comments, "I am very pleased to make today's announcement. It is our hope that the successful business development makeup of our Board demonstrates a firm commitment to the creation of a world-class company founded on solid principals aimed at increasing shareholder value, stakeholder success and broad consumer acceptance."

Additional details of the Company's business, finances, appointments and agreements can be found as part of the Company's continuous public disclosure as a reporting issuer with the Securities and Exchange Commission ("SEC") available at www.sec.gov. For more information please visit www.cannabistherapy.com.

About Cannabis Therapy Corp. (OTCQB: CTCO)
Cannabis Therapy Corp. aims to develop and market safe, phytocannabinoid-based medicinal products and to apply rigorous manufacturing and quality control standards to become a global leader in the research, development, manufacturing, testing and marketing of cannabinoid ingredients and therapies. For more information visit www.cannabistherapy.com.

Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the availability of additional funding; and the Company's business, product development, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including, the Company's current reports on Form 8-K. The Company does not undertake to update these forward-looking statements.

ON BEHALF OF THE BOARD,

Soren Mogelsvang, President & CEO
Cannabis Therapy Corp.

Contact Information